Publications

Publications

Peer Reviewed Publications:

  1. Gu F, Karnik R, Wang A, Alexis F, Levy-Nissenbaum E, Hong S, Langer R, Farokhzad OC. Targeted Nanoparticles for Cancer Therapy.  NanoToday, 2007; Vol. 2, No. 3, pg 14-21.
  2. Zhang L, Gu FX, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in Medicine: Therapeutic Applications and Developments. Clinical Pharmacology and Therapeutics, 2007; 83(5):761-9.
  3. Wang AZ, Bagalkot V, Vasilliou C, Gu F, Alexis F, Zhang LF, Shaikh M, Yuet K, Cima M, Langer R, Kantoff PW, Bander NH, Jon S, Farokhzad OC. Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy. ChemMedChem. 2008, 3(9):1311-5.
  4. Wang AZ, Gu F, Zhang LF, Chan JM, Radovic-Moreno A, Shaikh MR, Farokhzad OC. Biofunctionalized Targeted Nanoparticles for Therapeutic Applications. Expert Opinions on Biological Therapy, 2008; 8(8):1063-70.
  5. Gu F, Zhang LF, Teply B, Mann N, Wang A, Radovic-Moreno AF, Langer R, Farokhzad OC. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block co-polymers. Proceedings of the National of Academy of Sciences, 2008, 105(7): 2586-91.
  6. Tam WF, Gu TL, Chen J, Lee BH, Bullinger L, Fröhling S, Wang A, Monti S, Golub TR, Gilliland DG. Oncogenic tyrosine kinases upregulate Id1 in leukemic cells. Blood, 2008, 112(5):1981-92.
  7. Zhang L, Chan J, Gu F, Rhee JW, Wang AZ, Radovic-Moreno A, Alexis F, Langer R, Farokhzad OC. Self-assembled lipid-polymer hybrid nanoparticles: A robust drug delivery platform. ACS Nano, 2008, 2(8); 1696-1702.
  8. Alexis F, Basto P, Levy-Nissenbaum E, Radovic-Moreno AF, Zhang L, Pridgen E, Wang AZ, Marein SL, Westerhof K, Molnar LK, Farokhzad OC. HER-2-Targeted Nanoparticle-Affibody Bioconjugates for Cancer Therapy. ChemMedChem, 2008, 3(12): 1839-1843
  9. Wang AZ, Yuet K, Zhang LF, Gu FX, Huynh-Le M, Radovic-Moreno AF, Kantoff PW, Bander NH, Langer R, Farokhzad OC. ChemRad Nanoparticles: A Novel Multifunctional Nanoparticle Platform for Targeted Delivery of Concurrent Chemoradiation. Nanomedicine, 2010 Apr; 5(3): 361-8. PMCID: PMC2901911
  10. Merkel TJ, Jones SW, Herlihy KP, Kersey FR, Shields AR, Napier M, Wang AZ, Bear JE, DeSimone JM. Using Mechano-biological Mimicry to Extend Circulation Times of Red Blood Cell Replicas. Proceedings of the National Academy of Sciences, 2011 Jan 11;108(2):586-91. PMCID: PMC3021010
  11. McRee AJ, Cowherd S, Wang AZ, Goldberg RM. Chemoradiation Therapy in the Management of Gastrointestinal Malignancies. Future Oncol. 2011 Mar;7(3): 409-26.
  12. Werner ME, Karve S, Sukumar R, Cummings ND, Copp JA, Chen RC, Zhang T, Wang AZ. Folate targeted nanoparticle delivery of chemo- and radio-therapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials, 2011 Nov;32(33):8548-54. 
  13. Werner ME, Copp JA, Karve S, Cummings ND, Sukumar R, Napier M, Chen RC, Cox AD, Wang AZ. Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependent on the timing of radiotherapy. ACS Nano, 2011 Nov 22;5(11):8990-8.
  14. Karve S, Werner ME, Cummings ND, Sukumar R, Wang EC, Zhang YA, Wang AZ. Formulation of diblock polymeric nanoparticles through nanoprecipitation technique. J Vis Exp. 2011 Sep 20;(55)
  15. Holmes JA, Wang ZA, Hoffman KE, Hendrix LH, Rosenman JG, Carpenter WR, Godley PA, Chen RC. Is Primary Prostate Cancer Treatment Influenced by Likelihood of Extraprostatic Disease? A Patterns of Care Study Using the Surveillance Epidemiology and End Results Database. Int J Radiat Oncol Biol Phys, 2012 Jan 31.
  16. Werner ME, Foote MB, Wang AZ. Chemoradiotherapy of Human Tumors: Novel Approaches from Nanomedicine. Current Pharmaceutical Design, 2012;18(19):2830-7.
  17. Di Pasqua AJ, Huckle JE, Kim JK, Chung Y, Wang AZ, Jay M, Lu X. Preparation of Neutron Activatable Holmium Nanoparticles for the Treatment of Ovarian Cancer Metastases. Small, Apr 10;8(7):997-1000.
  18. Wang AZ, Langer R, Farokhzad OC. Nanoparticle Delivery of Cancer Drugs. Annual Reviews of Medicine. 2012;63:185-98.
  19. Karve S, Werner ME, Sukumar R, Cummings ND, Copp JA, Wang EC, Li C, Chen RC, Pacold ME, Wang AZ. Revival of the Abandoned Therapeutic Wortmannin by Nanoparticle Drug Delivery. Proceedings of the National of Academy of Sciences, 2012 May 22;109(21):8230-5.
  20. Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, Wallen EM, Crane JM, Kim WY, Rathmell WK, Godley PA, Whang YE. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer. British Journal of Urology.  2012 Sep 27.
  21. Stokes WA, Hendrix LH, Royce TJ, Allen IM, Godley PA, Wang AZ, Chen RC. Racial differences in time from prostate cancer diagnosis to treatment initiation, a population-based study. Cancer, 2013 Jul 1;119(13):2486-93.
  22. Miller SM, Wang AZ. Nanomedicine in chemoradiation. Ther Deliv. 2013 Feb;4(2):239-50.
  23. Werner ME, Cummings ND, Sukumar R, Sethi M, Wang EC, Moore DT, Dees EC, Wang AZ. Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys,  2013 Jul 1;86(3):463-8.
  24. Gallagher SA, Smith AB, Matthews JE, Potter CW, Woods ME, Raynor M, Wallen EM, Kimryn Rathmell W, Whang YE, Kim WY, Godley PA, Chen RC, Wang A, You C, Barocas DA, Pruthi RS, Nielsen ME, Milowsky MI. Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database-UNC GOLD. Urol Oncol. 2013 Feb 19 pii:S1078-1439(12)
  25. Goldberg MS, Hook SS, Wang AZ, Bulte JW, Patri AK, Uckun FM, Cryns VL, Hanes J, Akin D, Hall JB, Gharkholo N, Mumper RJ. Biotargeted nanomedicines for cancer: six tenets before you begin. Nanomedicine (Lond). 2013 Feb;8(2):299-308.
  26. Chapman S, Dobrovolskaia M, Farahani K, Goodwin A, Joshi A, Lee H, Meade T, Pomper M, Ptak K, Rao J, Singh R, Sridhar S, Stern S, Wang AZ, Weaver JB, Woloschak G, Yang L. Nanoparticles for cancer imaging: the good, the bad and the promise. Nanotoday, Epub.
  27. Wang EC, Sinnott R, Werner ME, Sethi M, Whitehurst AW, Wang AZ. Differential Cell Responses to Nanoparticle Docetaxel and Small Molecule Docetaxel at a Sub-Therapeutic Dose Range. Nanomedicine:Nanotechnology Biology  and Medicine. 2013 Aug 3. pii: S1549-9634(13)00353-5.
  28. Chu KS, Schorzman AN, Finniss MC, Bowerman CJ, Peng L, Luft JC, Madden AJ, Wang AZ, Zamboni WC, Desimone JM. Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy. Biomaterials, 2013 Nov;34(33):8424-9.
  29. Chen RC, Hendrix LH, Carpenter WR, Bainbridge J, Wang AZ, Nielsen ME, Godley PA. Receipt of guideline-concordant treatment in elderly prostate cancer patients. Int J Radiat Oncol Biol Phys., 2014 Feb: 88 (2):332-338.
  30. Xu Z, Chen RC, Wang AZ, Kress A, Foskey M, Qin A, Cullip T, Tracton G, Chang S, Tepper J, Yan D, and Chaney E. Comparison of User-Directed and Automatic Mapping of the Planned Isocenter to Treatment Space for Prostate IGRT," International Journal of Biomedical Imaging, vol. 2013, Article ID 892152, 12 pages, 2013
  31. Sethi M, Sukumar R, Karve S, Werner ME, Wang EC, Moore DT, Kowalczyk SR, Zhang L, Wang AZ. Effect of Drug Release Kinetics on Nanoparticle Therapeutic Efficacy and Toxicity. Nanoscale, 2014, 6 (4), 2321 – 2324
  32. Wang AZ, Farokhzad OC. Current Progress of Aptamer-Based Molecular Imaging. J Nucl Med. 2014 Feb 13. Epub
  33. Wang AZ, Tepper JE. Nanotechnology in Radiation Oncology. J Clin Oncol. 2014, in press.


Non-peer Reviewed Publications

1.     Kim, S.I., Swanson, T.A., Wang, AZ. Underground Clinical Vignettes USMLE Step 2: Surgery. (4th Edition). Lippincott Williams & Wilkins/Wolters Kluwer Health. 2007.

2.     Wang AZ, Gu FX, Farokhzad OC. Nanoparticles for cancer diagnosis and therapy. Chapter: Nanoparticles for Cancer Diagnosis and Therapy. Safety of Nanoparticles. Springer Science+Business Media, LLC. 2009.

3.     Wang AZ, Radovic-Moreno AF, Farokhzad OC. Chapter: Biologically Targeted Nanoparticles as Cancer Therapeutics. Bio-inspired Nanotechnology and Nanomaterials. Nova Science Publishers. 2009.

4.     Tepper JE, Wang AZ. Improving local control in rectal cancer: radiation sensitizers or radiation dose? Journal of Clinical Oncology, J Clin Oncol. 2010 Apr 1;28(10):1623-4.

5.     Zhang T, Wang AZ. Definitions of Biochemical Failure. The Textbook of Prostate Cancer. Springer, in press.

6.     Wang, AZ. Nanoparticle drug delivery: focusing on the therapeutic cargo. Nanomedicine,  2012 Oct;7(10):1463-5.

7.     Wang, AZ. Giving failed drugs a fresh chance: a new direction for nanoparticle drug delivery. Expert Rev. Med. Devices, 2012 Sep;9(5):445-7.

Patents
  1. Wang AZ, Farokhzad OC, Zhang LF, Radovic-Moreno A, Gu F, Langer R. Drug delivery system for pharmaceuticals and radiation. International PCT Patent Application No.: PCT/US08/082655 (12/2008).
  2. Wang Z, Werner M, Chen R, Byrne J, Karve S, Desimone J. Delivery for brachytherapy and associated methods. International PCT Patent Application No.: PCT/US2010/053357 (10/2010).
  3. Wang Z, Pacold M, Werner M, Karve S. Novel Wortmannin Nanoparticles and Uses Thereof. US PCT/US2011/ 61431689 (01/2011).
  4. Wang Y, Reid LM, Yamauchi M, Cui C, Wang AZ, Werner M. Biomatrix Scaffolds. PCT/US11/42805 (07/11).